Canada· CA-DIN-02290960
MABCAMPATH
A alemtuzumab product containing alemtuzumab, registered in Canada by SANOFI-AVENTIS CANADA INC. The same ATC class is registered in 11 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Alemtuzumab is registered in 11 of 19 countries.
Countries holding a registration under ATC L04AG06 (alemtuzumab), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 7 of them publish a price we can compare per daily dose
Alemtuzumab · ATC L04AG06
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- ALEMTUZUMAB
- Manufacturer
- SANOFI-AVENTIS CANADA INC
- Country
- Canada (CA)
- ATC code
- L04AG06
- ATC class
- Alemtuzumab
- Defined daily dose
- 0.13 mg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
338 interactions on record for alemtuzumab.
Graded by severity as the source publishes them — 24 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Alemtuzumab · interactions on record
338 records
- 24 severe
- 314 moderate
Most severe, free to view
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Alemtuzumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandLemtradaSanofi Belgium
- United KingdomLemtrada 12mg/1.2ml concentrate for solution for infusion vialsSanofi
- CzechiaCAMPATH
- United StatesCampathGenzyme Corporation
- BelgiumLemtrada 12 mgSanofi Belgium
- IcelandLemtradaSanofi Belgium
- Japanアレムツズマブ（遺伝子組換え）サノフィ
- NetherlandsLEMTRADA 12 mg concentraat voor oplossing voor infusieSanofi Belgium
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lemtrada
- Liechtenstein · Lemtrada
- Norway · Lemtrada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e252c85a-3dbe-46f0-b5c9-28ed54c03217 GET /v1/drugs/e252c85a-3dbe-46f0-b5c9-28ed54c03217?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02290960",
"form": "SOLUTION",
"class": "Human",
"routes": [
"INTRAVENOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L04AG06",
"schedule": [
"Prescription",
"Schedule D"
],
"drug_code": "77636",
"strengths": [
"30 MG"
],
"ahfs_class": null,
"substances": [
"ALEMTUZUMAB"
],
"product_categorization": null
}See everything about alemtuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.